After debuting with 370$ million capital raise in September 2024, Candid Therapeutics, a San Diego-based biotechnology company specializing in T-cell …
Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company, has announced preclinical Proof-of-Concept (PoC) results for a precision cancer vaccine …
Relay Therapeutics, a clinical-stage precision medicine company, has announced updated interim clinical data for its investigational allosteric PI3Kα inhibitor, RLY-2608, …
We use cookies to personalise content and to analyse our traffic.
You consent to our cookies if you continue to use our website. Read more details in our
cookies policy.